{"result": "(\"entity\"<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>ORGANIZATION<|>The National Comprehensive Cancer Network (NCCN) is an organization that provides clinical practice guidelines in oncology, including guidelines for thyroid carcinoma.)\n##\n(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association is a professional organization that provides management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.)\n##\n(\"entity\"<|>SPENCER CA<|>PERSON<|>Spencer CA is a researcher who has published work on the challenges of serum thyroglobulin measurement in the presence of Tg autoantibodies.)\n##\n(\"entity\"<|>THYROID CARCINOMA<|>EVENT<|>Thyroid carcinoma is a type of cancer that affects the thyroid gland and is the subject of various clinical guidelines and studies.)\n##\n(\"entity\"<|>TIROXINA<|>EVENT<|>Tiroxina is a medication used in the treatment of thyroid conditions, including thyroid carcinoma.)\n##\n(\"entity\"<|>TIROGLOBULINA<|>EVENT<|>Tiroglobulina is a protein that is measured in patients with thyroid cancer to assess treatment response and recurrence risk.)\n##\n(\"relationship\"<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>AMERICAN THYROID ASSOCIATION<|>Both organizations provide guidelines and recommendations for the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>SPENCER CA<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>Spencer CA has contributed to the research and guidelines published by the NCCN regarding thyroid cancer<|>6)\n##\n(\"relationship\"<|>THYROID CARCINOMA<|>AMERICAN THYROID ASSOCIATION<|>The American Thyroid Association provides management guidelines specifically for thyroid carcinoma<|>8)\n##\n(\"relationship\"<|>TIROXINA<|>THYROID CARCINOMA<|>Tiroxina is used as a treatment in patients with thyroid carcinoma<|>9)\n##\n(\"relationship\"<|>TIROGLOBULINA<|>THYROID CARCINOMA<|>Tiroglobulina levels are monitored in patients with thyroid carcinoma to evaluate treatment response<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , en ausencia de contraindicaciones para su supresión.\n\nReferencias:\n- Haddad, RI, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma Version 1. © 2016 National Comprehensive Cancer Network, Inc; 2016. Disponible en: NCCN.org\n- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.\n- Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(1):1-122.\n- Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab. 2004;89:3702-4.\n\n## 39. En un paciente con carcinoma papilar de tiroides en tratamiento con tiroxina en dosis sustitutiva (TSH 1,7 mUI/ml) se objetiva una tiroglobulina de 2,1 ng/ml con anticuerpos antitiroglobulina negativos. Tras estímulo con TSHhr (TSH > 80 mUI/ml), el rastreo con 113I es negativo y la tiroglobulina estimulada es de 17,6 ng/ml con anticuerpos antitiroglobulina negativos. En esta situación, ¿cuál de las siguientes afirmaciones es falsa?\n\nA. Hay un 30% de posibilidades de que evolucione espontáneamente a la normalización.\nB. No requiere ninguna medida adicional de tratamiento ni de seguimiento, solo observación regular.\nC. Hay un 20% de posibilidades de recurrencia estructural.\nD. En este caso, el riesgo de mortalidad específica por cáncer de tiroides es inferior a un 1%.\n\n## COMENTARIO\n\nLa situación del paciente referido puede catalogarse como una respuesta bioquímica incompleta, ya que no hay evidencia estructural de tumor, pero los niveles de tiroglobulina que presenta son claramente elevados. Concretamente se define esta categoría cuando la tiroglobulina con TSH suprimida es igual o superior a 1 ng/ml o estimulada igual o superior a 10 ng/ml, siempre con Ac. antitiroglobulina negativos, como es el caso que nos ocupa.\n\nLa evolución a largo plazo de los pacientes encuadrados en esta categoría de respuesta al tratamiento es variable, pudiendo presentar una recidiva estructural tumoral, lo que sucede en aproximadamente un 20%, pero también, hasta en un 30% de los casos, puede evolucionar hacia la normalización de los niveles de tiroglobulina. Por lo tanto, la opción A de la pregunta planteada contiene una afirmación verdadera, al igual que la opción C.\n\nEn cuanto a la opción B, es claramente falsa. Aunque el pronóstico general de los pacientes con respuesta bioquímica incompleta es bueno, de forma que la mayoría de ellos, al final del periodo de seguimiento, se encuentran libres de enfermedad, no es así en todos los casos, existiendo riesgo de recidiva tumoral, por lo que una vigilancia activa es obligatoria. Además, se recomienda una supresión parcial de la TSH endógena para minimizar este riesgo de recidiva. Concretamente, en este grupo de pacientes se recomienda que la TSH se mantenga entre 0,1 y 0,5 mUI/l, teniendo en cuenta el riesgo inicial de recidiva, los niveles de tiroglobulina y su evolución en el tiempo, así como los riesgos de la supresión de la TSH.\n\nFinalmente, la opción D es verdadera. Como se ha expuesto previamente, el pronóstico de estos pacientes es bueno, no habiéndose descrito mortalidad tras un seguimiento de 10 años en diversas series publicadas.\n---\n# TIROIDES 3\n\n## Tabla 3. Categorías de respuestas en el cáncer diferenciado de tiroides\n\n| Respuesta | Descripción |\n|-----------|-------------|\n| Respuesta excelente | • Imagen negativa y Tg ultrasensible < 0,2 ng/ml o estimulada < 1 ng/ml<br>• Muy bajo riesgo de recurrencia (1-4%) y <1% de mortalidad |\n| Respuesta bioquímica incompleta | • Imagen negativa y Tg elevada ≥ 1 ng/ml bajo supresión o estimulada ≥ 10 ng/ml o anticuerpos anti-Tg en ascenso<br>• Más del 50% evolucionan a respuesta excelente<br>• El 20% desarrollan enfermedad estructural |\n| Respuesta estructural incompleta | • Evidencia o identificación de metástasis locorregionales o a distancia<br\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}